What drove the GNCA stock drop after hours on 05 Feb 2026?

The after-hours move reflects a tiny traded print at **$0.0001**, thin volume (**30,268**) and lingering Chapter 11 restructuring risk. No recent positive clinical or financing news reduced demand for GNCA stock.

What is Meyka AI’s current rating for GNCA stock?

Meyka AI rates GNCA with a score out of 100: **58.59 | Grade C+ | Suggestion: HOLD**. The grade factors S&P and sector comparisons, financial growth, key metrics, forecasts, and analyst consensus.

Is there a realistic GNCA stock price target or forecast?

Meyka AI's forecast model projects a base case **$0.0001**, a recovery scenario **$0.0010**, and a stretch target **$0.0200**, each compared to the current **$0.0001**. Forecasts are projections and not guarantees.

Should investors trade GNCA stock given the low price?

Trading GNCA stock carries high liquidity and execution risk, plus operational uncertainty. We view GNCA as speculative; only traders who accept potential total loss should consider positions.

US Stocks

After Hours Top Loser 05 Feb 2026: GNCA Genocea NASDAQ at $0.0001, see liquidity

ByDanny Kontos February 6, 2026February 6, 2026

We saw GNCA stock plunge in after-hours trade on 05 Feb 2026, finishing at $0.0001 on NASDAQ in the United States after a -97.44% one-day move. This drop follows a thin intraday print, volume 30,268 shares, and a wide gap from the 50-day average price of $0.00 (reported $0.0047). GNCA Genocea Biosciences, Inc. remains a small-cap healthcare play with Chapter 11 proceedings in its history, and the market is pricing severe liquidity and execution risk into the shares.